Home » Stocks » HROW

Harrow Health, Inc. (HROW)

Stock Price: $7.95 USD 0.39 (5.16%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $7.80 -0.15 (-1.89%) Mar 5, 4:24 PM
Market Cap 204.68M
Revenue (ttm) 46.88M
Net Income (ttm) -1.85M
Shares Out 25.92M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $7.95
Previous Close $7.56
Change ($) 0.39
Change (%) 5.16%
Day's Open 7.49
Day's Range 7.01 - 7.98
Day's Volume 273,276
52-Week Range 3.33 - 11.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 week ago

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for...

GlobeNewsWire - 3 weeks ago

Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021

Zacks Investment Research - 2 months ago

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Other stocks mentioned: CDNA, BMXMF, AMEH
Zacks Investment Research - 2 months ago

Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the Ameri...

GlobeNewsWire - 3 months ago

NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow's Chief Executive Officer, and Andrew Boll, Harrow's Chief Financi...

Seeking Alpha - 3 months ago

Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health's Letter to ...

Benzinga - 4 months ago

Harrow Health (NASDAQ: HROW) will be releasing its next round of earnings this Monday, November 09. For all of the relevant information, here is your guide for Monday's Q3 earnings announcement.

Zacks Investment Research - 4 months ago

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarte...

Zacks Investment Research - 4 months ago

Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 5 months ago

NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors.

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor Harrow Health.

GlobeNewsWire - 5 months ago

NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference...

Seeking Alpha - 6 months ago

Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 7 months ago

On Monday, August 10, Harrow Health (NASDAQ: HROW) will release its latest earnings report.

Zacks Investment Research - 7 months ago

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quar...

GlobeNewsWire - 7 months ago

The study published in Clinical Ophthalmology shows equivalent clinical outcomes to separately dosed eyedrops and a strong patient preference for the ImprimisRx proprietary combination drop th...

GlobeNewsWire - 8 months ago

NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3...

Zacks Investment Research - 8 months ago

Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...

Seeking Alpha - 9 months ago

Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 11 months ago

ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning telemedicine services ImprimisRx customers will have free access to the entire suite of Doxy.me award-wi...

GlobeNewsWire - 11 months ago

NASHVILLE, Tenn., March 17, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors.

Zacks Investment Research - 11 months ago

Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 11 months ago

Harrow Health, Inc. (HROW) CEO Mark Baum on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

Agreement expands locations served and access to new ImprimisRx formulations Agreement expands locations served and access to new ImprimisRx formulations

GlobeNewsWire - 11 months ago

ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery

GlobeNewsWire - 1 year ago

ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations...

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...

Seeking Alpha - 1 year ago

Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join t...

GlobeNewsWire - 1 year ago

BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...

About HROW

Harrow Health, together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye dro... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1998
CEO
Mark L. Baum
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
HROW
Full Company Profile

Financial Performance

In 2019, Harrow Health's revenue was $51.17 million, an increase of 23.67% compared to the previous year's $41.37 million. Earnings were $168,000, a decrease of -98.85%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 69.81% from the latest price.

Price Target
$13.50
(69.81% upside)
Analyst Consensus: Strong Buy